NO20005190D0 - Terapeutiske angiogene faktorer og metoder for deres anvendelse - Google Patents

Terapeutiske angiogene faktorer og metoder for deres anvendelse

Info

Publication number
NO20005190D0
NO20005190D0 NO20005190A NO20005190A NO20005190D0 NO 20005190 D0 NO20005190 D0 NO 20005190D0 NO 20005190 A NO20005190 A NO 20005190A NO 20005190 A NO20005190 A NO 20005190A NO 20005190 D0 NO20005190 D0 NO 20005190D0
Authority
NO
Norway
Prior art keywords
angiogenic factor
poly
carrier
pleiotrophin
animal
Prior art date
Application number
NO20005190A
Other languages
English (en)
Other versions
NO20005190L (no
Inventor
Kenneth J Colley
Original Assignee
Angiogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenix Inc filed Critical Angiogenix Inc
Publication of NO20005190D0 publication Critical patent/NO20005190D0/no
Publication of NO20005190L publication Critical patent/NO20005190L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20005190A 1998-04-17 2000-10-16 Terapeutiske angiogene faktorer og fremgangsmåter til anvendelse derav NO20005190L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8215598P 1998-04-17 1998-04-17
PCT/US1999/008420 WO1999053943A2 (en) 1998-04-17 1999-04-16 Therapeutic angiogenic factors and methods for their use

Publications (2)

Publication Number Publication Date
NO20005190D0 true NO20005190D0 (no) 2000-10-16
NO20005190L NO20005190L (no) 2000-11-30

Family

ID=22169397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005190A NO20005190L (no) 1998-04-17 2000-10-16 Terapeutiske angiogene faktorer og fremgangsmåter til anvendelse derav

Country Status (11)

Country Link
US (2) US20030185794A1 (no)
EP (1) EP1071445A2 (no)
JP (1) JP2002512200A (no)
CN (1) CN1379681A (no)
AU (1) AU760664B2 (no)
BR (1) BR9909717A (no)
CA (1) CA2329010A1 (no)
IL (1) IL139030A0 (no)
MX (1) MXPA00010110A (no)
NO (1) NO20005190L (no)
WO (1) WO1999053943A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106009B2 (en) * 1997-09-26 2012-01-31 Medical Therapies Limited Pharmaceutical composition for preventing or treating ischemic diseases
AU3471400A (en) * 1999-01-19 2000-08-07 Children's Hospital Of Philadelphia, The Compositions and methods for controlled delivery of virus vectors
US6903244B1 (en) 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
AU771904B2 (en) * 1999-06-22 2004-04-08 Research Development Foundation Enhanced wound coverage to enhance wound healing
JP2001064196A (ja) * 1999-08-24 2001-03-13 Meiji Milk Prod Co Ltd 創傷治癒促進組成物
US6364912B1 (en) * 1999-09-17 2002-04-02 Depuy Orthopeaedics, Inc. Pleiotrophin-based compositions for enhancing connective tissue repair
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
WO2001068158A1 (en) 2000-03-15 2001-09-20 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US20040023863A1 (en) * 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
EP1305337B1 (en) * 2000-06-14 2010-03-10 Georgetown University Pleiotrophin growth factor receptor alk for the treatment of proliferative, vascular and neurological disorders
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US6939540B1 (en) * 2000-07-31 2005-09-06 Cornell Research Foundation, Inc. Method of enhancing bone density
GB0113697D0 (en) 2001-06-06 2001-07-25 Smith & Nephew Fixation devices for tissue repair
EP1539214A4 (en) 2002-07-02 2008-01-02 Orthologic Corp Thrombin
CN1732022A (zh) * 2002-12-30 2006-02-08 血管技术国际股份公司 含有丝的支架移植物
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
JP4850709B2 (ja) * 2003-05-14 2012-01-11 ダニスコ・ユーエス・インコーポレーテッド 反復配列タンパク質ポリマーを使用する、活性剤の制御放出
WO2005001044A2 (en) * 2003-05-29 2005-01-06 Angiogenix, Inc. Compositions related to pleiotrophin methods and uses thereof
WO2005014022A1 (en) 2003-07-16 2005-02-17 Develogen Aktiengesellschaft Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
ES2375565T3 (es) 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
WO2005046746A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20060085062A1 (en) * 2003-11-28 2006-04-20 Medlogics Device Corporation Implantable stent with endothelialization factor
WO2005107817A2 (en) * 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
WO2006042197A2 (en) * 2004-10-11 2006-04-20 The Board Of Trustees Of The Leland Standford Junior University Use of del-1 in hair, bone and cartilage regeneration
JP4791770B2 (ja) * 2004-12-06 2011-10-12 株式会社セルシグナルズ 心筋障害又は心不全の治療もしくは予防組成物
US7595295B2 (en) * 2005-02-25 2009-09-29 Rush University Medical Center Use of pleiotrophin to promote neurogeneration
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8334259B2 (en) 2006-09-22 2012-12-18 The Board Of Regents, The University Of Texas System Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative
WO2008047904A1 (fr) * 2006-10-20 2008-04-24 National University Corporation Nagoya University Agent thérapeutique pour vasculopathie périphérique oblitérante et utilisation
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8288343B2 (en) 2007-03-30 2012-10-16 National University Corporation Nagoya University Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
CN101601858B (zh) * 2009-05-27 2012-09-19 上海交通大学 中期因子蛋白的用途及含该蛋白的医用装置
KR101953742B1 (ko) * 2010-02-24 2019-03-04 어드밴젠 인터내셔널 피티와이 리미티드 모발 손상 치료 또는 예방 방법 또는 모발 성장 촉진용 방법
CN102965387A (zh) * 2012-10-25 2013-03-13 中国科学院广州生物医药与健康研究院 Trx-hPTN融合蛋白及其生产方法
PT2996709T (pt) * 2013-05-15 2020-07-14 Univ Leland Stanford Junior Modulação da atividade do fator de crescimento epidérmico de ligação à heparina para cicatrização da membrana timpânica
WO2019143969A1 (en) * 2018-01-18 2019-07-25 Claudio Maldonado Treating microvascular dysfunction

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US465189A (en) * 1891-12-15 Overshoe attachment
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4369229A (en) * 1981-01-29 1983-01-18 The Kendall Company Composite hydrogel-forming article and method of making same
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4720507A (en) * 1984-03-05 1988-01-19 University Of Western Ontario Biological contraceptive and contraceptive technique for males
US4619913A (en) * 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4699788A (en) * 1984-08-20 1987-10-13 Trustees Of Boston University Angiogenic factor methods of extraction and method for producing angiogenesis
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4547784A (en) * 1984-12-24 1985-10-15 Polaroid Corporation Thermal recording system and method
US5496712A (en) * 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
US5641648A (en) * 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5641743A (en) * 1988-01-25 1997-06-24 American Cyanamid Company Therapeutic compositions and methods for use of heparin-binding brain mitogens
US5171842A (en) * 1988-01-25 1992-12-15 American Cyanamid Company Heparin-binding brain mitogens
US5270449A (en) * 1988-01-25 1993-12-14 American Cyanamid Company Methods for the isolation of heparin-binding brain mitogens
US5576017A (en) * 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5527856A (en) * 1988-11-21 1996-06-18 Collagen Corporation Method of preparing crosslinked biomaterial compositions for use in tissue augmentation
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5475052A (en) * 1988-11-21 1995-12-12 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5041497A (en) * 1989-04-10 1991-08-20 Allied-Signal Inc. Process for preparing co-poly(amides/peptides)
IL90193A (en) * 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
DE69018357T2 (de) * 1989-10-06 1995-09-21 President Of National Cancer C Mutein von HST-1 und seine Herstellung.
US6448381B1 (en) * 1990-01-08 2002-09-10 Barnes-Jewish Hospital DNA encoding heparin-binding growth factor
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5626863A (en) * 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5206354A (en) * 1990-11-23 1993-04-27 American Cyanamid Company Dna sequence encoding active fragment of fibroblast growth factor, hbf-2
ATE138687T1 (de) * 1990-11-23 1996-06-15 American Cyanamid Co Chimeres fibroblasten-wachstumsfaktor
EP0488196A3 (en) * 1990-11-30 1993-04-07 Takeda Chemical Industries, Ltd. Hst-2, a member of the heparin binding growth factor family
US5540928A (en) * 1991-02-27 1996-07-30 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
GB9210574D0 (en) * 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
FR2692582B1 (fr) * 1992-06-18 1998-09-18 Flamel Tech Sa Nouveaux derives reticulables de collagene, leur procede d'obtention et leur application a la preparation de biomateriaux.
US5469505A (en) * 1992-07-08 1995-11-21 Acs Wireless, Inc. Communications headset having a ball joint-mounted receiver assembly
DK0686045T3 (da) * 1993-02-23 2001-03-05 Genentech Inc Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
FR2701955B1 (fr) * 1993-02-26 1995-05-24 Paris Val Marne Universite Facteur de croissance de la famille de l'HARP, procédé d'obtention et applications.
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5491220A (en) * 1993-09-24 1996-02-13 Yeda Research And Development Co., Ltd. Surface loop structural analogues of fibroblast growth factors
GB9406094D0 (en) * 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US5540657A (en) * 1994-07-15 1996-07-30 Collagen Corporation Delivery device for injectable materials
WO1996002257A1 (en) * 1994-07-18 1996-02-01 Georgetown University Antisense oligonucleotides of pleiotrophin
JPH0827021A (ja) * 1994-07-22 1996-01-30 Mitsui Toatsu Chem Inc 医薬組成物
US5582937A (en) * 1994-10-12 1996-12-10 Bipolar Technologies, Inc. Bipolar battery cells, batteries and methods
US5551427A (en) * 1995-02-13 1996-09-03 Altman; Peter A. Implantable device for the effective elimination of cardiac arrhythmogenic sites
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
EP0998941B9 (en) * 1997-07-14 2007-03-14 Takashi Muramatsu Use of midkine or of anti-midkine antibodies
CA2304956C (en) * 1997-09-26 2013-12-03 Yoshihiro Yoshida Pharmaceutical composition for preventing or treating ischemic diseases
US6364912B1 (en) * 1999-09-17 2002-04-02 Depuy Orthopeaedics, Inc. Pleiotrophin-based compositions for enhancing connective tissue repair

Also Published As

Publication number Publication date
US20030202960A1 (en) 2003-10-30
NO20005190L (no) 2000-11-30
AU3495599A (en) 1999-11-08
AU760664B2 (en) 2003-05-22
CA2329010A1 (en) 1999-10-28
WO1999053943A3 (en) 2000-01-20
US20030185794A1 (en) 2003-10-02
CN1379681A (zh) 2002-11-13
BR9909717A (pt) 2000-12-26
WO1999053943A2 (en) 1999-10-28
MXPA00010110A (es) 2002-08-06
JP2002512200A (ja) 2002-04-23
IL139030A0 (en) 2001-11-25
EP1071445A2 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
WO1999053943A3 (en) Therapeutic angiogenic factors and methods for their use
EP1820495A3 (en) Microspheres for active embolization
ES2392061T3 (es) Matriz que comprende un esqueleto proteico de origen natural reticulado
FI955552A0 (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
JP2003525912A (ja) 遺伝子送達用核酸製剤および使用方法
AU5056196A (en) Hydrogel-forming, self-solvating absorbable polyester copolymers and methods for use thereof
IL160015A0 (en) Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
WO1998049300A3 (en) Truncated vegf-related proteins
WO2001037896A3 (en) Methods and compositions for administration of therapeutic reagents
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
NZ513404A (en) Iontophoresis, electroporation and combination patches for local drug delivery
WO2001072280A3 (en) Microspheres for gene therapy
JP3187410B2 (ja) 脳内投与用徐放性製剤
EP0804595A4 (no)
EA031883B1 (ru) Способ ингибирования и/или снижения образования рубцовой ткани
PT1295611E (pt) Preparações para transferência de oligonucleótidos
ES2277099T3 (es) Inmunoadyuvante.
KR100718077B1 (ko) 만노스화 키토산 유도체 및 이를 이용한 유전자 전달체
WO2000078358A2 (en) Hyaluronic acid microspheres for sustained gene transfer
ES2364812T3 (es) Formulaciones de ácido nucleico para su liberación génica.
RU2000129133A (ru) Терапевтические ангиогенные факторы и способы их применения
EP1326646A2 (de) Transferrin-polykation/dns-komplexe für die systemische therapie von tumorerkrankungen mit zytotoxischen proteinen
Shami Gene-enhanced tissue engineering: Applications for wound healing using cultured dermal fibroblasts transduced retrovirally with the PDGF-B gene: Breitbart AS, Mason JM, Urmacher C, et al. Ann Plast Surg 43: 632, 1999
Sayers et al. Genetically engineered neurotrophin secreting Schwann cells for the treatment of spinal cord injury
Wnek et al. Gene-Activated Matrix/Neil Davies

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application